Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer-Reference-Cited by-同舟云学术

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

Published:2023-08-29 Issue:1 Volume:20 Page:114-130
ISSN:1554-8627
Container-title:Autophagy
language:en
Short-container-title:Autophagy

Author:

Li Weihao¹²^ORCID,Zhou Chi¹²,Yu Long¹²,Hou Zhenlin¹²,Liu Huashan³,Kong Lingheng¹²,Xu Yanbo¹²,He Jiahua¹²,Lan Jin¹²,Ou Qingjian¹²,Fang Yujing¹²,Lu Zhenhai¹²,Wu Xiaojun¹²,Pan Zhizhong¹²,Peng Jianhong¹²,Lin Junzhong¹²

Affiliation:

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

2. Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

3. Department of Colorectal Surgery and Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Cell Biology,Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/15548627.2023.2249762

Reference52 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Colorectal cancer statistics, 2020

3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer